Striking that balance has been the challenge for companies attempting to set up B2B intellectual property exchanges in the life sciences. You talk about the problem, you don't solve it. You talk about the technology in terms of what it can do, what it has achieved, but not sufficient knowledge that you would disclose the inner workings of it. ActiveCyte, which focuses on biotech, asked pharmaceutical companies for their help designing its standard. ActiveCyte lets companies scroll through a diagram of a molecule's chemical structure, information about conditions it could be related to, and its research and patent history.
Users can search by criteria, and connect to other databases.
But intellectual property B2B executives say they know their service is only a beginning, and with so much at stake, any introduction is followed by months of due diligence and negotiation.